Milestone Pharmaceuticals Overview

  • Founded
  • 2005
Founded
  • Status
  • Public
  • Employees
  • 29
Employees
  • Stock Symbol
  • MIST
Stock Symbol
  • Share Price
  • $5.57
  • (As of Friday Closing)

Milestone Pharmaceuticals General Information

Description

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Stock Exchange
NAS
Primary Office
  • 1111 Doctor.-Frederik-Philips Boulevard
  • Suite 420
  • Montreal, Quebec H4M 2X6
  • Canada
+1 (514) 000-0000

Milestone Pharmaceuticals Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Milestone Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.57 $5.38 $3.98 - $8.24 $167M 29.9M 107K -$1.05

Milestone Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 78,626 70,005 97,855 256,218
Revenue 15,000 15,000 0 0
EBITDA (44,433) (42,980) (50,613) (57,843)
Net Income (44,346) (42,853) (49,967) (55,229)
Total Assets 105,799 119,849 149,974 123,428
Total Debt 631 698 941 514
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Milestone Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Milestone Pharmaceuticals‘s full profile, request access.

Request a free trial

Milestone Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for t
Pharmaceuticals
Montreal, Canada
29 As of 2021
00000
000000000 00000

0000000

a pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt molli
0000 000000000
Newark, CA
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00

0000000

prehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat
0000 000000000
Plymouth Meeting, PA
000 As of 0000
00000
0.000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Milestone Pharmaceuticals Competitors (85)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
InCarda Therapeutics Venture Capital-Backed Newark, CA 00 000.00 00000000000 000.00
0000000 0000000000 Formerly VC-backed Plymouth Meeting, PA 000 00000 00000000 00000
0000000 0000000000 Venture Capital-Backed Indianapolis, IN 0 000.00 0000000000 0 000.00
0000000000 0000000 Venture Capital-Backed Boston, MA 00 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed Schlieren, Switzerland 00 000.00 00000000000 000.00
You’re viewing 5 of 85 competitors. Get the full list »

Milestone Pharmaceuticals Patents

Milestone Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3283067-B1 Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof Active 14-Apr-2015 0000000000
JP-6785792-B2 Highly water-soluble salts of short-acting phenylalkylamine calcium channel blockers and their use Active 14-Apr-2015 00000000
JP-2018514527-A Highly water-soluble salts of short-acting phenylalkylamine calcium channel blockers and their use Granted 14-Apr-2015 0000000000
US-20210205258-A1 Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof Abandoned 14-Apr-2015 00000000
EP-3689344-A1 Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof Pending 14-Apr-2015 A61K9/08 0
To view Milestone Pharmaceuticals’s complete patent history, request access »

Milestone Pharmaceuticals Executive Team (13)

Name Title Board Seat Contact Info
Joseph Oliveto Chief Executive Officer & Board Member
Amit Hasija Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Jeff Nelson Chief Operating Officer
Francis Plat MD Chief Scientific Officer
Lorenz Muller Executive
You’re viewing 5 of 13 executive team members. Get the full list »

Milestone Pharmaceuticals Board Members (19)

Name Representing Role Since
Debra Liebert Domain Associates Board Member 000 0000
Joseph Oliveto Milestone Pharmaceuticals Chief Executive Officer & Board Member 000 0000
Lisa Giles Milestone Pharmaceuticals Board Member 000 0000
Michael Tomsicek Self Board Member 000 0000
Paul Truex Self Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Milestone Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial